Peptide Reference
Tirzepatide
Tirzepatide Peptide
A dual GIP/GLP-1 receptor agonist offering superior weight loss and glycemic control compared to GLP-1-only medications. The active ingredient in Mounjaro and Zepbound.
Status
approved
Category
weight loss
Typical cost
$1000-1600/month (brand), $200-500/month (compounded)
Mechanism
Activates both GIP and GLP-1 receptors, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite more effectively than GLP-1 agonists alone.
Potential benefits
- Superior weight loss vs GLP-1 only
- Improved HbA1c
- Reduced cardiovascular risk
- Enhanced satiety
- Better lipid profiles
- Sustained results
Reported side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Injection site reactions
- Gallbladder issues
- Potential thyroid tumors
Common dosing references
subcutaneous
2.5-15mg · Weekly
Ongoing
Research notes
SURMOUNT-1 - Tirzepatide for obesity
2022
Average 20.9% weight loss at 72 weeks with 15mg dose
SURPASS-2 - vs Semaglutide
2021
Superior HbA1c reduction and weight loss compared to semaglutide 1mg
Regulatory and sourcing notes
FDA-approved (Mounjaro for diabetes, Zepbound for weight loss). Also available from compounding pharmacies.
Prescription required for brand. Compounded versions available. Higher efficacy than semaglutide but more GI side effects initially.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides